Sponsor

CTI BioPharma

Clinical research sponsor

Published trials12

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

12 shown

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerNCT04404361 · lead sponsor · 2020-05-22

TERMINATED

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mLNCT00576225 · lead sponsor · 2007-09-01

WITHDRAWN

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00551733 · lead sponsor · 2007-08-01

TERMINATED

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.NCT00269828 · lead sponsor · 2005-12-01

TERMINATED

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerNCT00054210 · lead sponsor · 2003-01-01

TERMINATED

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung CancerNCT00054184 · lead sponsor · 2003-01-01

TERMINATED

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerNCT00054197 · lead sponsor · 2003-01-01

TERMINATED

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous TherapyNCT00004026 · lead sponsor · 1998-12-01

TERMINATED

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast CancerNCT01227408 · collaborator · 2009-02-01

WITHDRAWN

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)NCT00487669 · collaborator · 2006-10-01

COMPLETED

A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung CancerNCT00352690 · collaborator · 2006-04-01

TERMINATED

CT-2103 in Combination With Gemcitabine in Metastatic Breast CancerNCT00270907 · collaborator · 2005-12-01

COMPLETED

Sponsor roles

lead sponsor8

collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.